ARTICLE | Clinical News
Kahalalide F: Phase I data
June 14, 2004 7:00 AM UTC
PharmaMar S.A., Madrid, Spain Product: Kahalalide F Business: Cancer Molecular target: NA Description: Novel peptide isolated from Elysia rufescens Indication: Treat hormone-refractory prostate cancer...